Literature DB >> 20113453

Gravity sedimentation of granulocytapheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils.

Barbara J Bryant1, Yu Ying Yau, Phyllis J Byrne, David F Stroncek, Susan F Leitman.   

Abstract

BACKGROUND: Transfusion of granulocytapheresis concentrates can be limited by the volume of incompatible donor red blood cells (RBCs) in the component. Efficient reduction of RBCs in granulocyte units would result in safe transfusion of RBC-incompatible units. STUDY DESIGN AND METHODS: Granulocyte concentrates were collected by continuous-flow apheresis from granulocyte-colony-stimulating factor (G-CSF) and dexamethasone-stimulated volunteer donors, with 6% hydroxyethyl starch (HES) added continuously during apheresis as a RBC sedimenting agent to enhance granulocyte collection efficiency. After collection, the component was placed in a plasma extractor for 4 hours. A sharp line of demarcation between the starch-sedimented RBCs and the granulocyte-rich supernatant developed, and the supernatant was transferred to a sterilely docked transfer pack. RBC reduction and white blood cell recovery were determined.
RESULTS: Gravity sedimentation was performed on 165 granulocyte concentrates. Mean sedimentation time was 267 minutes (range, 150-440 min). RBC depletion was 92% (range, 71%-99%) with mean residual RBC content of 3.2 +/- 1.4 mL. Twelve percent of components contained less than 2 mL of RBCs. Mean granulocyte and platelet (PLT) recoveries were 80 and 81%, respectively. There were no transfusion reactions or signs of hemolysis after transfusion of 66 RBC-incompatible granulocyte concentrates (RBC volume, 1.6-8.2 mL). The remaining concentrates were used for topical or intrapleural applications.
CONCLUSIONS: RBCs were significantly reduced and granulocytes and PLTs effectively retained in G-CSF/steroid-mobilized granulocyte components collected with HES and processed by gravity sedimentation. This procedure allows safe transfusion of RBC-incompatible sedimented granulocyte units and may be used to expand the pool of available granulocyte donors for specific recipients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113453      PMCID: PMC3421031          DOI: 10.1111/j.1537-2995.2009.02576.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  19 in total

1.  Combined administration of G-CSF and dexamethasone for the mobilization of granulocytes in normal donors: optimization of dosing.

Authors:  W C Liles; E Rodger; D C Dale
Journal:  Transfusion       Date:  2000-06       Impact factor: 3.157

2.  Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation.

Authors:  T H Price; R A Bowden; M Boeckh; J Bux; K Nelson; W C Liles; D C Dale
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

3.  Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections.

Authors:  J J Lee; I J Chung; M R Park; H Kook; T J Hwang; D W Ryang; H J Kim
Journal:  Leukemia       Date:  2001-02       Impact factor: 11.528

4.  Effect of ABO incompatibility on the fate in vivo of 111Indium granulocytes.

Authors:  J McCullough; M Clay; M Loken; D Hurd
Journal:  Transfusion       Date:  1988 Jul-Aug       Impact factor: 3.157

5.  Granulocyte transfusion therapy in a child with chronic granulomatous disease and multiple red cell alloantibodies.

Authors:  L Depalma; S F Leitman; C S Carter; J I Gallin
Journal:  Transfusion       Date:  1989-06       Impact factor: 3.157

6.  Administration of G--CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G--CSF alone.

Authors:  D F Stroncek; Y Y Yau; J Oblitas; S F Leitman
Journal:  Transfusion       Date:  2001-08       Impact factor: 3.157

7.  Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions.

Authors:  G Illerhaus; K Wirth; A Dwenger; C F Waller; A Garbe; V Brass; H Lang; W Lange
Journal:  Ann Hematol       Date:  2002-04-03       Impact factor: 3.673

8.  Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors.

Authors:  S Rutella; L Pierelli; S Sica; R Serafini; P Chiusolo; U Paladini; F Leone; G Zini; G D'Onofrio; G Leone; N Piccirillo
Journal:  Cytotherapy       Date:  2003       Impact factor: 5.414

9.  Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study.

Authors:  J Bux; U Cassens; T Dielschneider; M Duchscherer; E Edel; H Eichler; C Haas; R Moog; H Peschke; C Peters; I Ryzenkov; P Schlenke; H Ullrich; M Wiesneth
Journal:  Vox Sang       Date:  2003-11       Impact factor: 2.144

Review 10.  Granulocyte transfusions in neutropenic patients: beneficial effects proven?

Authors:  C Peters
Journal:  Vox Sang       Date:  2009-01-29       Impact factor: 2.144

View more
  6 in total

1.  Cord blood serum harvesting by hydroxyethyl starch: a fetal bovine serum alternative in expansion of umbilical cord-derived mesenchymal stem cells.

Authors:  Maryam Samareh Salavati Pour; Reza Vahidi; Mahla Lashkari; Ali Derakhshani; Zahra Ameri; Alireza Farsinejad
Journal:  Cytotechnology       Date:  2020-06-29       Impact factor: 2.058

2.  Red blood cell sedimentation of Apheresis Granulocytes.

Authors:  Michelle A Lodermeier; Karen M Byrne; Willy A Flegel
Journal:  Transfusion       Date:  2017-08-16       Impact factor: 3.157

3.  Polycythemia in an infant secondary to granulocyte transfusions.

Authors:  Olufolake Adisa; Jeanne E Hendrickson; Courtney K Hopkins; Howard M Katzenstein; Cassandra D Josephson
Journal:  Pediatr Blood Cancer       Date:  2011-03-02       Impact factor: 3.167

Review 4.  Granulocyte transfusions in the management of invasive fungal infections.

Authors:  Kamille A West; Juan Gea-Banacloche; David Stroncek; Sameer S Kadri
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

5.  Preparation of granulocyte concentrates by apheresis: collection modalities in the USA.

Authors:  R G Strauss; H G Klein; S F Leitman; T H Price; B Lichtiger; F Martinez; H W Reesink; S Panzer
Journal:  Vox Sang       Date:  2011-02-14       Impact factor: 2.144

6.  Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia.

Authors:  José A Casado; Antonio Valeri; Rebeca Sanchez-Domínguez; Paula Vela; Andrea López; Susana Navarro; Omaira Alberquilla; Helmut Hanenberg; Roser Pujol; José-Carlos Segovia; Jordi Minguillón; Jordi Surrallés; Cristina Díaz de Heredia; Julián Sevilla; Paula Rio; Juan A Bueren
Journal:  J Clin Invest       Date:  2022-08-01       Impact factor: 19.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.